×
About 3,898 results

ALLMedicine™ Vaccinia Center

Research & Reviews  1,414 results

Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vac...
https://doi.org/10.1038/s41434-021-00308-z
Gene Therapy; Shimada M, Wang H et. al.

Jan 7th, 2022 - Previously, we developed a chimeric adenovirus type 5 with type 35 fiber (Ad5/35), which has high tropism to dendritic cells and low hepatoxicity. For further clinical use, we constructed two recombinant vectors expressing human immunodeficiency v...

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
https://clinicaltrials.gov/ct2/show/NCT00669734

Jan 5th, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of delivering two standard doses of the PANVAC-F (fowlpox) (falimarev) vaccine administered intratumorally in conjunction with subcutaneous injections of PANVAC-V (vaccinia) (inalimarev) followe...

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
https://clinicaltrials.gov/ct2/show/NCT04895449

Jan 5th, 2022 - The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein (S). This will be a phase Ib multi-center study in approximately 60 adults aged 18-64 years. Part A (N=24 seronegative subjects). E...

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRI...
https://clinicaltrials.gov/ct2/show/NCT04574583

Jan 4th, 2022 - Background: Combination immunotherapy approaches are being actively explored to further improve responses, enhance clinical benefit, and overcome resistance to PD(L)-1 agents in cancer participants. Interleukin-8 (IL-8) is a pro-inflammatory chemo...

An increase in glycoprotein concentration on extracellular virions dramatically alters ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746760
PLoS Pathogens; Monticelli SR, Bryk P et. al.

Dec 29th, 2021 - The extracellular virion (EV) form of Orthopoxviruses is required for cell-to-cell spread and pathogenesis, and is the target of neutralizing antibodies in the protective immune response. EV have a double envelope that contains several unique prot...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  85 results

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
https://clinicaltrials.gov/ct2/show/NCT04895449

Jan 5th, 2022 - The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing a stabilized SARS-CoV-2 spike protein (S). This will be a phase Ib multi-center study in approximately 60 adults aged 18-64 years. Part A (N=24 seronegative subjects). E...

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
https://clinicaltrials.gov/ct2/show/NCT00669734

Jan 5th, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of delivering two standard doses of the PANVAC-F (fowlpox) (falimarev) vaccine administered intratumorally in conjunction with subcutaneous injections of PANVAC-V (vaccinia) (inalimarev) followe...

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRI...
https://clinicaltrials.gov/ct2/show/NCT04574583

Jan 4th, 2022 - Background: Combination immunotherapy approaches are being actively explored to further improve responses, enhance clinical benefit, and overcome resistance to PD(L)-1 agents in cancer participants. Interleukin-8 (IL-8) is a pro-inflammatory chemo...

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03354728

Dec 28th, 2021 - PRIMARY OBJECTIVES: I. To investigate the optimal dose of multi-antigen CMV-modified vaccinia ankara vaccine (Triplex) in CMV-positive pediatric patients receiving human leukocyte antigen (HLA) matched, mismatched, or haploid-identical hematopoiet...

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
https://clinicaltrials.gov/ct2/show/NCT04228783

Dec 22nd, 2021 - The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactu...

see more →

News  56 results

CDC: Vials Contain No Trace of Virus That Causes Smallpox
https://www.medscape.com/viewarticle/963382

Nov 19th, 2021 - PHILADELPHIA (AP) — Frozen vials labeled "Smallpox" that were discovered in a freezer at a vaccine research facility in Pennsylvania "contain no trace of virus known to cause smallpox," federal health officials said. The Centers for Disease Contro...

Novel Combinations on the Horizon in HCC
https://www.onclive.com/view/novel-combinations-on-the-horizon-in-hcc

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: This brings me to another layer of discussion, which is, if you recall, we spoke about the different layers of the BCSE. We spoke about the horizontal connection between the different lines of therapy. But...

5 Abstracts Offer Snapshot of Immunology Research
https://www.onclive.com/view/5-abstracts-offer-snapshot-of-immunology-research

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

High Points and Hurdles: Immunotherapy Moves Forward
https://www.onclive.com/view/high-points-and-hurdles-immunotherapy-moves-forward

Dec 5th, 2020 - Illustration depicts T lymphocytes attacking a migrating cancer cell. Novel ways to improve the ability of T lymphocytes to enhance immune response are under study. At this time last year, immunotherapy was in the limelight. Within a span of les...

Novel Concepts Include New Agents, Combinations
https://www.onclive.com/view/novel-concepts-include-new-agents-combinations

Dec 5th, 2020 - Oliver Sartor, MD Oncology specialists who treat patients with metastatic castration-resistant prostate cancer (mCRPC) can look forward to choosing from an expanding array of therapeutic tools, including regimens that couple immunotherapy with n...

see more →